{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:25:58Z","timestamp":1786980358691,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T00:00:00Z","timestamp":1543190400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00592-018-1257-1","type":"journal-article","created":{"date-parts":[[2018,11,25]],"date-time":"2018-11-25T23:03:07Z","timestamp":1543186987000},"page":"341-354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"56","author":[{"given":"Carla","family":"Carnovale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Dassano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"D\u2019Addio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Gentili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Magni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Radice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fiorina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,26]]},"reference":[{"key":"1257_CR1","unstructured":"World Health Organization. Hepatitis C. Available from: \n                    http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/\n                    \n                  . Accessed 2 Jun 2018"},{"key":"1257_CR2","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.2337\/dc05-1995","volume":"29","author":"A Lecube","year":"2006","unstructured":"Lecube A, Hern\u00e1ndez C, Genesc\u00e0 J, Sim\u00f3 R (2006) Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis. Diabetes Care 29:1140\u20131149","journal-title":"Diabetes Care"},{"key":"1257_CR3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.510290235","volume":"29","author":"AL Mason","year":"1999","unstructured":"Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L et al (1999) Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29:328\u2013333","journal-title":"Hepatology"},{"key":"1257_CR4","doi-asserted-by":"publisher","first-page":"586","DOI":"10.4239\/wjd.v5.i5.586","volume":"5","author":"A Antonelli","year":"2014","unstructured":"Antonelli A, Ferrari SM, Giuggioli D, Di Domenicantonio A, Ruffilli I, Corrado A et al (2014) Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. World J Diabetes 5:586\u2013600","journal-title":"World J Diabetes"},{"key":"1257_CR5","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.3748\/wjg.v18.i14.1642","volume":"18","author":"C Naing","year":"2012","unstructured":"Naing C, Mak JW, Ahmed SI, Maung M (2012) Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol 18:1642\u20131651","journal-title":"World J Gastroenterol"},{"key":"1257_CR6","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/hep.21208","volume":"43","author":"MS Lai","year":"2006","unstructured":"Lai MS, Hsieh MS, Chiu YH, Chen TH (2006) Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 43:1295\u20131302","journal-title":"Hepatology"},{"key":"1257_CR7","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1002\/hep.22251","volume":"47","author":"BJ Veldt","year":"2008","unstructured":"Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP et al (2008) Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 47:1856\u20131862","journal-title":"Hepatology"},{"key":"1257_CR8","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S0002-9440(10)63408-6","volume":"165","author":"T Kawaguchi","year":"2004","unstructured":"Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T et al (2004) Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 165:1499\u20131508","journal-title":"Am J Pathol"},{"key":"1257_CR9","doi-asserted-by":"publisher","first-page":"12361","DOI":"10.3748\/wjg.v21.i43.12361","volume":"21","author":"F Parvaiz","year":"2015","unstructured":"Parvaiz F, Manzoor S, Iqbal J, Sarkar-Dutta M, Imran M, Waris G (2015) Hepatitis C virus NS5A promotes insulin resistance through IRS-1 serine phosphorylation and increased gluconeogenesis. World J Gastroenterol 21:12361\u201312369","journal-title":"World J Gastroenterol"},{"key":"1257_CR10","doi-asserted-by":"publisher","first-page":"34733","DOI":"10.1074\/jbc.M403886200","volume":"279","author":"H Shi","year":"2004","unstructured":"Shi H, Tzameli I, Bj\u00f8rbaek C, Flier JS (2004) Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J Biol Chem 279:34733\u201334740","journal-title":"J Biol Chem"},{"key":"1257_CR11","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.3748\/wjg.v17.i36.4055","volume":"17","author":"M Basaranoglu","year":"2011","unstructured":"Basaranoglu M, Basaranoglu G (2011) Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis. World J Gastroenterol 17:4055\u20134062","journal-title":"World J Gastroenterol"},{"key":"1257_CR12","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/1743-422X-8-474","volume":"18","author":"F Parvaiz","year":"2011","unstructured":"Parvaiz F, Manzoor S, Tariq H, Javed F, Fatima K, Qadri I (2011) Hepatitis C virus infection: molecular pathways to insulin resistance. Virol J 18:474","journal-title":"Virol J"},{"key":"1257_CR13","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.2337\/dc05-2509","volume":"29","author":"A Lecube","year":"2006","unstructured":"Lecube A, Hern\u00e1ndez C, Genesc\u00e0 J, Sim\u00f3 R (2006) Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study. Diabetes Care 29:1096\u20131101","journal-title":"Diabetes Care"},{"key":"1257_CR14","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1053\/j.gastro.2004.12.049","volume":"128","author":"M Romero-G\u00f3mez","year":"2005","unstructured":"Romero-G\u00f3mez M, Del Mar Viloria M, Andrade RJ, Salmer\u00f3n J, Diago M, Fern\u00e1ndez-Rodr\u00edguez CM et al (2005) Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128:636\u2013641","journal-title":"Gastroenterology"},{"key":"1257_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jhep.2007.07.026","volume":"48","author":"H Poustchi","year":"2008","unstructured":"Poustchi H, Negro F, Hui J, Cua IH, Brandt LR, Kench JG et al (2008) Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 48:28\u201334","journal-title":"J Hepatol"},{"key":"1257_CR16","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.2337\/dc06-0456","volume":"29","author":"R Sim\u00f3","year":"2006","unstructured":"Sim\u00f3 R, Lecube A, Genesc\u00e0 J, Esteban JI, Hern\u00e1ndez C (2006) Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care 29:2462\u20132466","journal-title":"Diabetes Care"},{"key":"1257_CR17","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.cgh.2010.01.022","volume":"8","author":"A Delgado-Borrego","year":"2010","unstructured":"Delgado-Borrego A, Jordan SH, Negre B, Healey D, Lin W, Kamegaya Y (2010) Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol 8:458\u2013462","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1257_CR18","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2337\/dc17-0485","volume":"40","author":"J Hum","year":"2017","unstructured":"Hum J, Jou JH, Green PK, Berry K, Lundblad J, Hettinger BD (2017) Improvement in glycemic control of type 2 diabetes after successful treatmen of hepatitis C virus. Diabetes Care 40:1173\u20131180","journal-title":"Diabetes Care"},{"key":"1257_CR19","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/jmv.24954","volume":"90","author":"A Ciancio","year":"2018","unstructured":"Ciancio A, Bosio R, Bo S, Pellegrini M, Sacco M, Vogliotti E et al (2018) Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. J Med Virol 90:320\u2013327","journal-title":"J Med Virol"},{"key":"1257_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/infdis\/jix517","volume":"217","author":"CS Chaudhury","year":"2017","unstructured":"Chaudhury CS, Sheehan J, Chairez C, Akoth E, Gross C, Silk R et al (2017) No improvement in hemoglobin A1c following hepatitis C viral clearance in patients with and without HIV. J Infect Dis 217:47\u201350","journal-title":"J Infect Dis"},{"key":"1257_CR21","first-page":"1","volume":"20","author":"JR Carvalho","year":"2018","unstructured":"Carvalho JR, Velosa J, Serejo F (2018) Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication-comparison of the new direct-acting antiviral agents with the old regimens. Scand J Gastroenterol 20:1\u20137","journal-title":"Scand J Gastroenterol"},{"key":"1257_CR22","unstructured":"Prospero international prospective register of systematic reviews. Available from: \n                    https:\/\/www.crd.york.ac.uk\/PROSPERO\/\n                    \n                  . Accessed 2 Jun 2018"},{"key":"1257_CR23","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264\u2013269","journal-title":"Ann Intern Med"},{"key":"1257_CR24","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008\u20132012","journal-title":"JAMA"},{"key":"1257_CR25","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/j.1365-2893.2006.00729.x","volume":"13","author":"PD Greenberg","year":"2006","unstructured":"Greenberg PD, Rosman AS, Eldeiry LS, Naqvi Z, Br\u00e4u N (2006) Decline in haemoglobin A1c values in diabetic patients receiving interferon-alpha and ribavirin for chronic hepatitis C. J Viral Hepat 13:613\u2013617","journal-title":"J Viral Hepat"},{"key":"1257_CR26","doi-asserted-by":"publisher","first-page":"528","DOI":"10.4103\/2230-8210.98004","volume":"16","author":"R Unnikrishnan","year":"2012","unstructured":"Unnikrishnan R, Anjana RM, Mohan V (2012) Drugs affecting HbA1c levels. Indian J Endocrinol Metab 16:528\u2013531","journal-title":"Indian J Endocrinol Metab"},{"key":"1257_CR27","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M et al The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from \n                    http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp\n                    \n                  . Accessed 2 Jun 2018"},{"key":"1257_CR28","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jech.52.6.377","volume":"52","author":"SH Downs","year":"1998","unstructured":"Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52:377\u2013384","journal-title":"J Epidemiol Community Health"},{"key":"1257_CR29","unstructured":"AASLD-IDSA Recommendations for testing, management, and treating hepatitis C. Monitoring patients who are starting hepatitis C treatment, are on treatment, or have completed therapy. Available from \n                    https:\/\/www.hcvguidelines.org\/sites\/default\/files\/full-guidance-pdf\/HCVGuidance_May_24_2018a.pdf\n                    \n                  . Accessed 2 Jun 2018"},{"key":"1257_CR30","first-page":"154","volume":"15","author":"SV Burgess","year":"2016","unstructured":"Burgess SV, Hussaini T, Yoshida EM (2016) Concordance of sustained virological response at weeks 4, 12 and 24 post-treatment of hepatitis c in the era of new oral direct-acting antivirals: A concise review. Ann Hepatol 15:154\u2013159","journal-title":"Ann Hepatol"},{"key":"1257_CR31","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/hep.23444","volume":"51","author":"M Martinot-Peignoux","year":"2010","unstructured":"Martinot-Peignoux M, Stern C, Maylin S, Ripault MP, Boyer N, Leclere L et al (2010) Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virological response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 51:1122\u20131126","journal-title":"Hepatology"},{"key":"1257_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","volume":"66","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver (2017) EASL recommendations on treatment of hepatitis C 2016. J Hepatol 66:153\u2013194","journal-title":"J Hepatol"},{"key":"1257_CR33","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1002\/jmv.24897","volume":"89","author":"S Abdel Alem","year":"2017","unstructured":"Abdel Alem S, Elsharkawy A, Fouad R, Adel E, Abdellatif Z, Musa S et al (2017) Improvement of glycemic state among responders to sofosbuvir-based treatment regimens: single center experience. J Med Virol 89:2181\u20132187","journal-title":"J Med Virol"},{"key":"1257_CR34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1159\/000484237","volume":"96","author":"A Ikeda","year":"2017","unstructured":"Ikeda A, Ikeda K, Takai A, Takahashi K, Ueda Y, Marusawa H et al (2017) Hepatitis C treatment with sofosbuvir and ledipasvir accompanied by immediate improvement in hemoglobin A1c. Digestion 96:228\u2013230","journal-title":"Digestion"},{"key":"1257_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/lt.25060","author":"J Beig","year":"2018","unstructured":"Beig J, Orr D, Harrison B, Gane E (2018) HCV eradication with new IFN free treatment improves metabolic profile in HCV-related liver transplant recipients. Liver Transpl. \n                    https:\/\/doi.org\/10.1002\/lt.25060","journal-title":"Liver Transpl"},{"key":"1257_CR36","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4093\/dmj.2017.41.4.316","volume":"41","author":"AA Dawood","year":"2017","unstructured":"Dawood AA, Nooh MZ, Elgamal AA (2017) Factors associated with improved glycemic control by direct-acting antiviral agent treatment in Egyptian type 2 diabetes mellitus patients with chronic hepatitis C genotype 4. Diabetes Metab J 41:316\u2013321","journal-title":"Diabetes Metab J"},{"key":"1257_CR37","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.cmi.2016.09.021","volume":"23","author":"C Fabrizio","year":"2017","unstructured":"Fabrizio C, Procopio A, Scudeller L, Dell\u2019Acqua R, Bruno G, Milano E (2017) HCV and diabetes: towards a \u2018sustained\u2019 glycaemic improvement after treatment with DAAs? Clin Microbiol Infect 23:342\u2013343","journal-title":"Clin Microbiol Infect"},{"key":"1257_CR38","unstructured":"Pashun RA, Shen NT, Jesudian A (2016) Markedly improved glycemic control in poorly controlled type 2 diabetes following direct acting antiviral treatment of genotype 1 hepatitis C. Case Rep Hepatol. 2016:7807921"},{"key":"1257_CR39","doi-asserted-by":"publisher","first-page":"215","DOI":"10.5604\/16652681.1231581","volume":"16","author":"JG Stine","year":"2017","unstructured":"Stine JG. Wynter JA, Niccum B, Kelly V, Caldwell SH, Shah NL (2017) Effect of treatment with direct acting antiviral on glycemic control in patients with diabetes mellitus and chronic hepatitis C. Ann Hepatol 16:215\u2013220","journal-title":"Ann Hepatol"},{"key":"1257_CR40","first-page":"567","volume":"33","author":"JF Huang","year":"2017","unstructured":"Huang JF, Huang CF, Yeh ML, Dai CY, Hsieh MH, Yang JF et al (2017) The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents. J Med Sci 33:567\u2013571","journal-title":"J Med Sci"},{"key":"1257_CR41","first-page":"462","volume":"72","author":"E Lenters-Westra","year":"2014","unstructured":"Lenters-Westra E, Schindhelm RK, Bilo HJ, Groenier KH, Slingerland RJ (2014) Differences in interpretation of haemoglobin A1c values among diabetes care professionals. Neth J Med 72:462\u2013466","journal-title":"Neth J Med"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00592-018-1257-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-018-1257-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-018-1257-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T19:23:41Z","timestamp":1574709821000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00592-018-1257-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,26]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["1257"],"URL":"https:\/\/doi.org\/10.1007\/s00592-018-1257-1","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"value":"0940-5429","type":"print"},{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,26]]},"assertion":[{"value":"13 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by the any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"For this type of study formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}